The fourth study offers promising findings from a study applying CD19-targeting chimeric antigen receptor (CAR) T-cell therapy to serious autoimmune diseases. They then tested the algorithm’s ability to tell the two types of MPNs apart in biopsies from 26 patients in Florida. “If you were to ask patients about their sickle cell disease care in the clinic, it is likely you would get a filtered response. Additional studies are being planned to further assess the use of intravenous and oral formulations of arsenic trioxide as frontline treatment for APL. Two new journals will be joining the Blood Journals portfolio in 2024, Blood Neoplasia (bloodneoplasia.org) and Blood Vessels, Thrombosis & Hemostasis (bloodvth.org).

Source: The Bubble December 10, 2023 09:30 UTC